Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

In Budget 2024, the government slashed GST (Goods and Services Tax) from three major cancer drugs: Trastuzumab Deruxtecan, ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

As Finance Minister Nirmala Sitharaman prepares to announce the Union Budget 2025 on February 1, experts have shared their ...

Lung cancer expert Triparna Sen delivered a seminar in the Cancer Biology Seminar Series at the University of Wisconsin Jan.

in combination with partner AstraZeneca's EGFR inhibitor Tagrisso (osimertinib) in non-small cell lung cancer (NSCLC) patients with MET amplification after progression on first-line EGFR inhibitor ...

The HER3-directed ADC will be tested in patients whose disease had progressed despite earlier treatment with EGFR inhibitors, including third-generation drugs like AZ's Tagrisso (osimertinib).

Background: Previous studies have found that teaspoons are commonly used to administer liquid medications to children. The capacity of household teaspoons ranges from 1.5 mL to 9 mL, potentially ...

Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical ...

Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, ...